Kelly Valla, PharmD, BCOP, On Common Adverse Effects Associated With Tazemetostat

For the latest installment of the “Product Profile”, ONCOLOGY® spoke with Kelly Valla, PharmD, BCOP, about tazemetostat (Tazverik) as therapy for patients with follicular lymphoma. Here, she discusses some toxicities that were associated with therapy, stating that not many adverse effects of grade 3 or 4 severity were reported.

Transcription:

In the clinical trial that garnered its approval by the FDA, tazemetostat was really well tolerated. Most toxicities were low-grade to grade 1/2—things like nausea and abdominal pain, [along with] some upper respiratory tract infections and other gastrointestinal disturbances. Overall, there were low rates of grade 3/4 toxicities, so this is a well-tolerated agent. [However, because] this agent was [just] approved, less than a year ago, we still have a lot of information to gather about what some of its long-term toxicities may be.

Reference:

Tazverik. Prescribing information. Epizyme; 2020. Accessed May 21, 2021. https://bit.ly/3oBelE6